Baan enters healthcare with Hiscom purchaseVanenberg Ventures-the privately held investment arm of enterprise resource planning (ERP) software developer Baan-has purchased Dutch healthcare information systems company Hiscom. Vandenberg Ventures
Vanenberg Ventures-the privately held investment arm of enterprise resource planning (ERP) software developer Baan-has purchased Dutch healthcare information systems company Hiscom. Vandenberg Ventures and Baan are also based in the Netherlands.
One of Baan's goals with Hiscom is to broaden the firm's current electronic patient record software to allow physicians to manage the complete interaction with the patient by including capabilities such as patient registration, data analysis, laboratory test ordering, and scheduling, said Otto van der Tang, an eight-year Baan veteran who assumed the post of managing director of Hiscom following the acquisition. Support for the management of medical images is also planned, van der Tang said.
"We believe that PACS are going to be an important component of such a patient interaction management system, but we don't believe that we should be developing this product ourselves," he said.
The Dutch firm is in discussion with a PACS software developer for inclusion of its technology in the Hiscom product portfolio.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.